Ligand Pharmaceuticals(FRA) LGDN

Market Cap€4.74B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€234.00

-0.85%

-2.00Today

Ligand Pharmaceuticals Financials at a Glance

Market Cap

€4.74B

Revenue (TTM)

€249.05

Net Income (TTM)

€169.14

EPS (TTM)

€8.02

P/E Ratio

29.67

Dividend

€0.00

Beta (Volatility)

0.98 (Low)

Dividend

€0.00

Beta (Volatility)

0.98 (Low)

Price

€234.00

Volume

Open

€240.00

Price

€234.00

Volume

Open

€240.00

Previous Close

€234.00

Daily Range

€234.00 - €240.00

52-Week Range

€135.00 - €280.00

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.98 (Low)

Price

€234.00

Volume

Open

€240.00

Previous Close

€234.00

Daily Range

€234.00 - €240.00

52-Week Range

€135.00 - €280.00

Estimated Earnings Date

N/A

LGDN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Todd Christopher Davis, MBA

Website

www.ligand.com

LGDN Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

21.80%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

3.37%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€4.74B

Shares Outstanding

19.94M

Volume

Avg. Volume

1.667

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Ligand Pharmaceuticals Performance Analysis

Ligand Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 186,726,732	-8.6%
2023	2023-12-31	EUR 121,461,571	-35.0%
2024	2024-12-31	EUR 154,510,889	27.2%
2025	2025-12-31	EUR 237,544,070	53.7%

Ligand Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -1.88	N/A
2023	2023-12-31	EUR 2.72	N/A
2024	2024-12-31	EUR -0.20	N/A
2025	2025-12-31	EUR 5.43	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€54.78

+1.3%

Gross Profit

€45.05

+1.4%

Gross Margin

82.24%

+1.1%

Market Cap

€4.74B

N/A

Market Cap/Employee

€114.28

N/A

Employees

N/A

Net Income

€41.72

+9.8%

EBITDA

€14.87

+0.9%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€1.87K

+2890.4%

Total Debt

€989.64

+202.3%

Accounts Receivable

€58.61

+1.7%

Inventory

€8.98

+0.7%

Long Term Debt

€988.69

+250.7%

Short Term Debt

€0.95

+1.0%

Return on Assets

12.44%

-1.4%

Return on Invested Capital

4.34%

+1.7%

Free Cash Flow

€20.89

+1.3%

Operating Cash Flow

€20.92

+1.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About LGDN

What is the current price of Ligand Pharmaceuticals?

Ligand Pharmaceuticals is trading at €234.00 per share.

What is the 52-week range for Ligand Pharmaceuticals?

Over the past 52 weeks, Ligand Pharmaceuticals has traded between €135.00 and €280.00.

How much debt does Ligand Pharmaceuticals have?

As of the most recent reporting period, Ligand Pharmaceuticals reported total debt of €989.64M.

How much cash does Ligand Pharmaceuticals have on hand?

Ligand Pharmaceuticals reported €880.52M in cash and cash equivalents in its most recent financial results.

What is Ligand Pharmaceuticals’s dividend yield?

Ligand Pharmaceuticals does not currently have a dividend yield.

Ligand Pharmaceuticals(FRA) LGDN

Ligand Pharmaceuticals Financials at a Glance

LGDN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ligand Pharmaceuticals

LGDN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ligand Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LGDN

What is the current price of Ligand Pharmaceuticals?

What is the 52-week range for Ligand Pharmaceuticals?

How much debt does Ligand Pharmaceuticals have?

How much cash does Ligand Pharmaceuticals have on hand?

What is Ligand Pharmaceuticals’s dividend yield?

Premium Investing Services